Conventional treatment of peripheral T-cell lymphomas: view from GELA and European perspective

Published: June 10, 2009
Abstract Views: 167
PDF: 227
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Patients with peripheral T cell lymphoma (PTCL) were treated until rituximab era with the same approach than B-cell lymphoma patients (BCL). In order to evaluate the impact of different therapeutic ap proaches, we looked at the results in different GELA prospective studies, which comprised over 900 T cell lymphoma patients since 1984. The reference arm was until now the intensive ACVBP regimen.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Gisselbrecht, G. (2009). Conventional treatment of peripheral T-cell lymphomas: view from GELA and European perspective. Hematology Meeting Reports (formerly Haematologica Reports), 2(13). https://doi.org/10.4081/hmr.v2i13.476